Cannabinoid receptors and their ligands

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• The endocannabinoid system comprises G protein-coupled cannabinoid receptors (CB1 and CB2) and endogenous agonists (endocannabinoids).
• CB1 receptors are predominantly found on neurons, influencing neurotransmitter release, while CB2 receptors are mainly on immune cells, affecting cytokine release.
• Endocannabinoids, such as anandamide, interact with these receptors and may have additional modes of action.

Purpose of the Study:

• To explore the structure and function of the endocannabinoid system.
• To review the development and therapeutic potential of cannabinoid receptor modulators (agonists and antagonists).
• To discuss the mechanisms of endocannabinoid inactivation and the potential of their inhibitors.

Main Methods:

• Literature review of cannabinoid receptor research.
• Analysis of preclinical and clinical data on cannabinoid receptor agonists and antagonists.
• Examination of endocannabinoid transport and degradation pathways.

Main Results:

• CB1/CB2 agonists are clinically used as anti-emetics and appetite stimulants.
• Potential therapeutic applications include managing pain, inflammatory disorders, multiple sclerosis, glaucoma, and cancer.
• Inhibitors of endocannabinoid inactivation show promise in reducing inflammatory pain and spasticity.

Conclusions:

• The endocannabinoid system presents diverse therapeutic opportunities for a range of conditions.
• Targeting cannabinoid receptors and endocannabinoid metabolism offers novel treatment strategies.
• Further research into selective agonists, antagonists, and enzyme inhibitors is warranted.